Frequency of Stimulant Treatment and of Stimulant-Associated Mania/Hypomania in Bipolar Disorder Patients
By Aliza P. Wingo, S. Nassir Ghaemi
Psychopharmacology Bulletin. 2008;41(4):37–47.

The Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Hospitalized Patients with Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Study
By Jean-Pierre Lindenmayer, David Brown, Sherry Liu, Martin Brecher, and Didier Meulien, on behalf of the Study 41 investigators

Cocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia
By Arija Maat, Annemarie Fouwels, Lieuwe de Haan

Are SNRIs More Effective than SSRIs? A Review of the Current State of the Controversy
By Michael E. Thase, MD. Psychopharmacol Bull.2008; 41(2):58-85.

Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of
a 26-Week Aripiprazole Study (Study CN138-010)
By Prakash S. Masand, MD, James Eudicone, MS, Andrei Pikalov, MD, PhD, Robert D. McQuade, PhD, Ronald N. Marcus, MD, Estelle Vester-Blokland, MD and Berit X. Carlson, PhD. Psychopharmacology Bulletin. 2008;41(2):12-23.

Bipolar-I Depression Outpatient Treatment Quality and Costs in Usual Care Practice
By Alisa B. Busch, MD, MS, Richard G. Frank, PhD, and Gary Sachs, MD. Psychopharmacology Bulletin. 2008;41(2):24-39.

A Placebo-Controlled Trial of Guanfacine for the Treatment of Posttraumatic Stress Disorder in Veterans
By Lori Davis, MD, L. Charles Ward, PhD, Ann Rasmusson, MD, Jason M. Newell, PhD, Elizabeth Frazier MS, and Steven M. Southwick, MD

Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Multicenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and d,l-Methylphenidate and Placebo in a Laboratory Classroom Setting
By Raul Silva, MD, Rafael Muniz, MD, Kevin McCague, MA, Ann Childress, MD, Matthew Brams, MD, and Alice Mao, MD

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial
By Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder
By Alexander Bystritsky, MD, Lauren Kerwin, BA, Jamie D. Feusner, MD, and Tanya Vapnik, PhD

Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening
By Robert MA Hirschfeld, MD, Joseph R. Calabrese, MD, Mark A. Frye, MD, Philip W. Lavori, PhD, Gary Sachs, MD, Michael E. Thase, MD, and Karen Dineen Wagner, MD, PhD

Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder:
A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials
By Donald S. Robinson, MD, Michelle L. Gilmor, PhD, Ying Yang, PhD, George Moonsammy, PhD, Albert J. Azzaro, PhD, Dan A. Oren, MD, and Bryan J. Campbell, PharmD

Awareness of Metabolic Concerns and Perceived Impact of Pharmacotherapy in Patients with Bipolar Disorder:
A Survey of 500 US Psychiatrists
By Trisha Suppes, MD, PhD, Susan L. McElroy, MD, and Robert Hirschfeld, MD

Donepezil for Cognitive Decline Following Coronary Artery Bypass Surgery: A Pilot Randomized Controlled Trial
By P. Murali Doraiswamy, MD, Michael A. Babyak, PhD, Therese Hennig, PA-C, Ranak Trivedi, PhD, William D. White, MPH, Joseph P. Mathew, MD, Mark F. Newman, MD, and James A. Blumenthal, PhD

The Speed of Onset of Action of Alprazolam-XR Compared to Alprazolam-CT in Panic Disorder
By David V. Sheehan, MD, MBA, Kathy Harnett Sheehan, PhD, and B.A. Raj, MD

Prospective Study to Evaluate the Efficacy of Aripiprazole as a Monotherapy in Patients with Severe Chronic Posttraumatic Stress Disorder: An Open Trial
By Gerardo Villarreal, MD, Lawrence A. Calais, RN, CCRC, Jose M. Cañive MD, S. Laura Lundy, BS,
Jacob Pickard, MA, and Gregory Toney, PharmD

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
By Larry Alphs,MD,PhD,John Panagides,PhD, and Scott Lancaster,MS

Positron Tomographic Emission Study of Olfactory Induced Emotional Recall in Veterans with and without Combat-Related Posttraumatic Stress Disorder
By Eric Vermetten, MD, PhD, Christian Schmahl, MD, Steven M. Southwick, MD, and J. Douglas Bremner, MD

Treatment Characteristics and Illness Burden Among European Americans, African Americans, and Latinos in the First 2,000 Patients of the Systematic Treatment Enhancement Program for Bipolar Disorder
Jodi M. Gonzalez, PhD, Peter Thompson, MD, Michael Escamilla, MD, Mako Araga, MS, Vivek Singh, MD, Niamh Farrelly, MD, Michael E. Thase, MD,
David J. Miklowitz, PhD, and Charles L. Bowden, MD

Effect of Mirtazapine Orally Disintegrating Tablets on Health-Related Quality of Life in Elderly Depressed Patients with Comorbid Medical Disorders: A Pilot Study
By Indira Varia, MD, Srimathi Venkataraman, MBBS, Caroline Hellegers, MA, Kenneth Gersing, MD, and P. Murali Doraiswamy, MD

Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia
By Vicki L. Ellingrod, PharmD, BCPP, Jeffrey R. Bishop, PharmD, MS, Jessica Moline, BS, Ying-Chi Lin, MS, and Del D. Miller, PharmD, MD

Citalopram Versus Amitriptyline in Elderly Depressed Patients with or without Mild Cognitive Dysfunction: A Danish Multicentre Trial in General Practice
By Claus Rosenberg, MD, Lise Lauritzen, MD, Jørgen Brix, MD, Jørgen B. Jørgensen, MD, Palle Kofod,MD, and Liselotte Been Bayer

Atypical Antipsychotics and Pituitary Neoplasms in the WHO Database
By P. Murali Doraiswamy, MD, Gisela Schott, MD, MPH, Kristina Star, RN, Ralph Edwards, MD, and Bruno Mueller-Oerlinghausen, MD

Suicide Risk Analysis Among Patients Assigned to Psychotropics and Placebo
By Arif Khan, MD, Russell L. Kolts, PhD. Amy E. Brodhead, MS, K. Ranga Krishnan, MD, and Walter A. Brown, MD

A Randomized Controlled Trial of Paroxetine for Non-Cardiac Chest Pain
By P. Murali Doraiswamy, MD, Indira Varia, MD, Caroline Hellegers, MA, H. Ryan Wagner, PhD, Greg L. Clary, MD, John L. Beyer, MD, L. Kristin Newby, MD, John F. O’Connor, MD, Katherine L. Beebe, PhD, Christopher O’Connor, MD, and K. Ranga R. Krishnan, MD

Reliability and Validity of the Yale-Brown Obsessive-Compulsive
Scale in Schizophrenia Patients
By Lieuwe de Haan, MD, PhD, Britt Hoogeboom, MD, Nico Beuk, MD, Luuk Wouters, Peter M.A.J. Dingemans, PhD, and Don H. Linszen, MD, PhD

Brief Report: Paroxetine in Younger and Adult Individuals at High Risk for Suicide
By Mark S. Bauer, MD, Stephen R. Wisniewski, PhD, Jane N. Kogan, PhD, Lauren B. Marangell, MD, Michael E. Thase, MD, and Gary Sachs, MD,
for the STEP-BD Investigators